For women with ovarian cancer, early identification of BRCA mutations can help determine the most appropriate treatment plan, and if the mutation is germline, can also support
Whilst germline BRCA testing for women with ovarian cancer is now commissioned by NHS England, funding for tumour testing remains limited.4,5 Therefore, to support identification of these women, AstraZeneca is providing a tumour BRCA testing service free of charge at certain sites in the UK.
Here you can find out more about BRCA testing, what the AstraZeneca
Tumour BRCA testing service
AstraZeneca are offering a tumour BRCA testing service free of charge at specified collaboration laboratories for patients who meet the eligibility criteria. This is to ensure patients who have a somatic BRCAm are identified and are given the opportunity to access treatments such as Lynparza.
Who is eligible for this service?
Patients who are eligible for this service are those that have ovarian cancer and either a known negative germline BRCA mutation status or an unknown germline BRCA mutation status. Patients must have received at least two prior lines of treatment (i.e. patient is third line or beyond).
How to access the service
You can access the service by completing the relevant AstraZeneca tumour BRCA testing form (below) and sending this, along with the tumour sample, to one of the AstraZeneca collaboration laboratories. The results should be returned 4-6 weeks after receipt of patient form and sample. The two collaboration laboratories AstraZeneca are currently working with to offer this service are:
All Wales Genetic Laboratory, Cardiff
Address: All Wales Genetics Laboratory, Institute of Medical
Genetics, University Hospital of Wales, Cardiff CF14 4XW
Tel: 02920 742641
Genomic Diagnostic Laboratory, Manchester
Genomic Diagnostics Laboratory Genetic Medicine (6th Floor)
St. Mary’s Hospital Oxford Road
Manchester M13 9WL
Tel: 0161 276 3265/6122
The testing process is straightforward and can be completed in several simple steps.